A Clinical Study to Assess the Effects of JoyRise Recovery Powder on Mitigating Alcohol Aftereffects.

Not Applicable

Completed

• Conditions: Anxiety; Cognitive Impairment; Alcohol Aftereffects

• Registration Number: NCT06575972
• Lead Sponsor: Joyrise

Brief Summary

This study assesses the effectiveness of JoyRise Recovery Powder in reducing alcohol aftereffects, cognitive impairment, and anxiousness among participants aged 35-54 who consume alcohol. Participants will be randomly assigned to either the JoyRise group or a placebo group. The study will measure hangover symptoms, cognitive function, and overall well-being through a series of questionnaires and cognitive tests at baseline, 30 minutes after product consumption, and 4 hours later.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-25
• Status Verified: 2024-08
• Primary Completion: 2024-08-01
• Study Completion: 2024-08-01
• Study First Submitted: 2024-08-23
• Study First Submitted QC: 2024-08-26
• Last Update Submitted: 2024-08-26
• Study First Posted: 2024-08-28
• Last Update Posted: 2024-08-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Aged 35-54, male or female
• Regular alcohol consumption
• Event planned within one month that involves alcohol consumption
• Willingness to avoid new medications or supplements during the study period
• Must confirm that they will not drive while under the influence of alcohol.

Exclusion Criteria

• Anyone not in good health.
• Anyone who has any chronic health conditions such as oncological or psychiatric disorders.
• Anyone who has any known serious allergic reactions that require the use of an Epi-Pen.
• Anyone who is pregnant, breastfeeding, or trying to conceive.
• Anyone who cannot/ will not commit to the study protocol.
• Anyone with a history of substance abuse.
• Anyone who has undergone an invasive medical procedure in the six months prior to the study, or has a procedure planned during the study duration.
• Anyone currently using any medications that may affect their response to alcohol or impact hangover symptoms, such as diuretics (water pills) or medication for hypertension.
• History of severe reactions or sensitivity to alcohol.
• Anyone currently taking glutathione.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Reduction in Symptoms Associated with Alcohol Aftereffects	Baseline and 30 minutes after product consumption on the day following alcohol consumption.	Measurement of the reduction in alcohol aftereffects using the Alcohol Hangover Questionnaire (AHQ). Participants will self-report their symptoms, such as headache, nausea, and tiredness.

Secondary Outcome Measures

Name	Time	Method
Reduction in Feelings of Anxiousness	Baseline and 30 minutes after product consumption on the day following alcohol consumption.	Measurement of reduction in feelings of anxiousness using self-reported questionnaires. Participants will rate their anxiety levels to determine if the product provides a calming effect.
Improvement in Cognitive Function	Baseline and 30 minutes after product consumption on the day following alcohol consumption.	Measurement of cognitive function using two cognitive tests: Feature Match (which assesses focus and processing). Participants will complete this assessment to determine any changes in cognitive function.
Increased User Satisfaction with Overall Well-being	Baseline and 4+ hours after product consumption on the day following alcohol consumption.	Measurement of user satisfaction with overall well-being through self-reported questionnaires. Participants will rate their satisfaction with their physical and mental state post-alcohol consumption.

Trial Locations

Locations (1)

Citruslabs; 🇺🇸 Santa Monica, California, United States